GlaxoSmithKline plc’s candidate RSV vaccines and the hepatitis B therapy, GSK 3228836, were singled out by CEO Emma Walmsley during the company’s third-quarter briefing for analysts on 28 October.
GSK Upbeat On RSV Vaccines, Hepatitis B Therapy
Walmsley Flags Future Growth Drivers
GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.
